NewAmsterdam Pharma Company N.V. Ordinary Shares NAMS
Analyst Ratings
- Consensus
- Buy — 5 Buy · 1 Hold · 0 Sell (6 analysts)
- Avg. Price Target
- $45.33 (+139.9% upside)
Key Stats
- Today's Range
- $18.50 – $19.39
- 50-Day Range
- $18.50 – $26.88
- 52-Week Range
- $18.50 – $42.20
- Volume
- 1.71 million shs
- Average Volume
- 1.52 million shs
- Market Cap
- $2.27 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.01%
- Days to Cover
- 1.00
About NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Related Stocks
Compare head-to-head: NAMS vs LLY·NAMS vs JNJ·NAMS vs ABBV·NAMS vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.